AI in Action: Transforming Pharma Industry with AUTOMA+ 2025

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025 is a hub for decision-makers and digital innovators for exchanging insights on the integration of AI within pharma operations. To bring on the networking discussions, the Congress is held in Vösendorf, Austria on November 24-25.

The rapid adoption of AI tools is bringing major transformations and making a profound impact across various industries, and pharmaceutical sector is no exception. Some pharma players, for instance, Eli Lilly, have invested in AI services to enhance specific R&D functions, focusing on areas such as AI-driven lab automation and medical reporting. At the same time, Bayer is transforming health and nutrition by harnessing artificial intelligence technologies to catalyse faster product development and improve the way the company manufactures and delivers products to the customers. In addition, Genentech, a member of the Roche Group, created “The ‘lab in a loop’”, a mechanism by which the company brings generative AI to drug discovery and development, meaning that data from the lab and clinic are used to train AI models, and then the trained models are used to make predictions on drug targets and therapeutic molecules.

AUTOMA+ 2025 is set to present companies’ latest strategies and ideas of using AI across the entire value chain: packaging and labelling processes, manufacturing, labs, logistics and more.

Automation combined with AI is a huge opportunity that we should harvest together. It is not just a trend, so it will stay forever
Harald Schnidar

The speakers' lineup of AUTOMA+ 2025 includes leading experts from top companies, who are going to share their expertise on AI implementation: Albocensa, Bayer Austria Ges.m.b.H., Automators GmbH, Acino Pharma AG, LETI Pharma, Sapio Sciences, Innowise, Cipla Ltd, SCARLETRED Holding GmbH and others.

“Automation combined with AI is a huge opportunity that we should harvest together. It is not just a trend, so it will stay forever”, said Harald Schnidar, CEO and Founder of SCARLETRED Holding GmbH. There are new AI developments and automation procedures, which are uptaken by pharma industry very quickly. This way, there are companies, who are quick in delivering, so, I think, it’s a perfect match.”

SCARLETRED Holding GmbH develops certified software as a medical device products and AI-powered data analysis services. These approaches standardise the process of skin imaging to objectify disease and treatment assessment, as well as to accelerate data collection in clinical trials and medical routine.

This year, Harald Schnidar joins the executive opening panel “Smart Pharma: leveraging digital technologies of tomorrow”, covering clinical skin drug R&D and remote patient care with the usage of AI.

Giving a comment during this discussion, Nandan Kulkarni, Head of Diagnostics and Medical Technologies, pointed out that digitalisation plays a key role in patient-centric ecosystem: “Digitalisation is one of the important elements to bring access and affordability. We are in the era where digitalisation is our only solution to reach millions of patients in chronic therapies, at the same time making sure we are creating impact on their lives.” Nandan Kulkarni also added that in the next five years, AI and phone applications are going to converge and create a digital ecosystem for all the patients across the world.

Partaking last year, Vitaly Levashov, Leading Product Consultancy in Innowise, revealed the key point that he got at AUTOMA+: “The most interesting insight was the increasing emphasis on automation and AI integration in various sectors, particularly healthcare and pharmaceuticals. Decisions highlighted how technology can streamline operations, reduce cost and enhance patients outcomes, which resonated strongly with current industry challenges.”

Within this edition, Innowise is going to take part in the leaders talk “AI-powered pharma: unmasking the future”. Roman Sen, Head of IT and Life Sciences, along with the speakers from ZETA GmbH, Sapio Sciences and Takeda going to discuss digital innovative approaches for tackling limitations, AI in remote patient care and implementation of AI and digital solutions in healthcare system.

As AI becomes more integrated into pharmaceutical processes, events such as AUTOMA+ helps companies to deepen their understanding on integrating AI tools and establish valuable connections to work on it together.

More about AI technologies presented at AUTOMA+ 2025: https://sh.bgs.group/304

Source: BGS Group

01.09.2025